A randomized, double-masked study to evaluate the effect of omega-3 fatty acids supplementation in meibomian gland dysfunction
Oleñik A, Jiménez-Alfaro I, Alejandre-Alba N, Mahillo-Fernández I
Clinical interventions in aging · 79 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
Según la declaración de financiación del texto completo.
Publicación
- Publicado
- 2013-08-01 · Clin Interv Aging · vol. 8 · pág. 1133
- Editorial
- Dove Medical Press
- Citado
- 90 citas · más que el 98% de estudios similares · 8.2× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 19 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY-NC
- Áreas de investigación
- Ocular Surface and Contact Lens · Fatty Acid Research and Health · Glaucoma and retinal disorders
- Palabras clave
- meibomian gland dysfunction, omega-3 fatty acids, dietary supplementation, tear film stability, tear film break-up time, ocular surface disease, artificial tears, Schirmer test, meibography, corneal staining
- MeSH
- meibomian glands, humans, eyelid diseases, fatty acids, omega-3, treatment outcome, double-blind method, dietary supplements, adult, aged, aged, 80 and over, middle aged, spain, female, male, young adult
4 autores
- Andrea Oléñik🇪🇸Hospital Universitario Fundación Jiménez Díaz
- Jiménez-Alfaro🇪🇸Hospital Universitario Fundación Jiménez Díaz
- Alejandre🇪🇸Hospital Universitario Fundación Jiménez Díaz
- Ignacio Mahíllo
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Dysfunction of the meibomian gland (MG) is among the most frequent causes of ophthalmological symptoms. The inflammation seen in meibomian gland dysfunction (MGD) is part of its pathogenesis, and evidence of the antioxidant-inflammatory properties of omega-3 fatty acids suggests this to be an appropriate treatment for MGD.
Objective
We aimed to assess the effectiveness of omega-3 fatty acids versus placebo, in improving the symptoms and signs of MGD.
Methods
We conducted a randomized and double-mask trial of 3 months duration. We enrolled 61 patients who presented with symptomatic MGD and no tear instability (defined as tear breakup time [TBUT] <10 seconds). Participants were randomly assigned to two homogeneous subgroups. For patients in group A, the study treatment included cleaning the lid margins with neutral baby shampoo and use of artificial tears without preservatives, plus a placebo oral agent. For patients in group B, the study treatment included cleaning the lid margins with neutral baby shampoo and use of artificial tears without preservatives, plus oral supplementation with omega-3 fatty acids. We performed the following tests: (1) TBUT; (2) Schirmer I test; (3) Ocular Surface Disease Index© (OSDI©; Allergan, Inc., Irvine, CA, USA); (4) MG expression; (5) evaluation of lid margin inflammation; and (6) interpalpebral and corneal dye staining.
Results
After 3 months of evaluation, the mean OSDI, TBUT, lid margin inflammation, and MG expression presented improvement from the baseline values, in group B (P < 0.01, P < 0.001, P < 0.0001, P < 0.0001, respectively). The Schirmer test results were also improved and statistically significant (P < 0.01).
Conclusion
Oral omega-3 fatty acids, 1.5 grams per day, may be beneficial in the treatment of MGD, mainly by improving tear stability.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.